Erythrodermic psoriasis treated with apremilast

Main Article Content

John Arcilla
Daniel Joe
Johnathan Kim
Yohanan Kim
VuAnh N. Truong
Navin Jaipaul *
(*) Corresponding Author:
Navin Jaipaul | Navin.Jaipaul@va.gov

Abstract

Erythroderma is a rare potentially deadly exfoliative dermatitis characterized by diffuse cutaneous erythema which may be associated with multi-organ dysfunction. Therefore, it is imperative to recognize and treat it promptly. Erythrodermic psoriasis is the most common form of erythroderma. Management of this condition is largely based on aggressive supportive care and the use of anti-inflammatory immunosuppressive and biologic agents. We describe a case of psoriatic erythroderma which was triggered by withdrawal from systemic steroids and successfully treated with apremilast and cyclosporine. Apremilast induced atrial fibrillation limited its continued use after the initial response period.

Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biography

Navin Jaipaul, Department of Medicine, Loma Linda University School of Medicine and Department of Medicine, VA Loma Linda Healthcare System, Loma Linda, CA

Department of Medicine

Division of Nephrology

Associate Professor of Medicine